Brolucizumab Suppliers & Bulk Manufacturers
Available Forms: injection (prefilled syringe)
Available Strengths: 120 mg/mL
Reference Brands: Beovu (USA/EU)
Category:
Opthalmology
Brolucizumab is a humanized monoclonal single-chain antibody fragment (scFv) that targets vascular endothelial growth factor A (VEGF-A). It is used to treat neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).
Brolucizumab is available in injection (prefilled syringe)
and strengths such as 120 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Brolucizumab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Brolucizumab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Brolucizumab is an advanced anti-vascular endothelial growth factor (anti-VEGF) therapy used for the treatment of neovascular (wet) age-related macular degeneration (nAMD), a serious eye condition that can lead to progressive vision loss. It is marketed under the brand name Beovu and developed by Novartis. Brolucizumab works by inhibiting VEGF-A, a protein responsible for the growth of abnormal blood vessels and fluid leakage in the retina. By blocking this pathway, the medicine helps reduce retinal swelling, improve visual outcomes, and slow disease progression.
The drug received approval from the United States Food and Drug Administration (US-FDA) in October 2019 for the treatment of nAMD, followed by approval in the European Union in February 2020. Its approval was supported by two major Phase 3 clinical trials, HAWK and HARRIER, which demonstrated the drug’s efficacy and safety with extended dosing intervals of every 8 to 12 weeks in many patients after the loading phase. Brolucizumab is administered as an intravitreal injection by an ophthalmology specialist and is designed to provide durable disease control with fewer injections compared to some earlier anti-VEGF therapies.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing